About the Barcelona Clinic Liver Cancer (BCLC) Staging System
Work top-down, because performance status and liver function can settle the stage before tumour burden is even considered. Performance status 3–4 or end-stage liver function is stage D; portal invasion, extrahepatic spread or performance status 1–2 is stage C. Only then does burden decide: a single nodule of 2 cm or less is stage 0, a single larger nodule or 2–3 nodules all 3 cm or less is stage A, and multifocal disease — more than 3 nodules, or 2–3 nodules with at least one above 3 cm — is stage B. That last definition is the clarification the 2026 update added. A single nodule stays stage A however large it is, which is the rule most often got wrong.
Formula
Assessed in this order:
1. PS 3–4 OR end-stage liver function → Stage D
2. Portal invasion / extrahepatic spread OR PS 1–2 → Stage C
3. Otherwise (PS 0, preserved function), by burden:
single nodule ≤ 2 cm → Stage 0
single nodule > 2 cm, or 2–3 nodules all ≤ 3 cm → Stage A
> 3 nodules, or 2–3 nodules with one > 3 cm → Stage B- Performance status
- ECOG 0–4. Checked first — it can override any tumour burden.
- Liver function
- Preserved (Child-Pugh A/B) versus end-stage (Child-Pugh C, not transplantable).
- Multifocal (stage B)
- More than 3 nodules, or 2–3 nodules with at least one above 3 cm. This wording is the clarification introduced in the 2026 update.
- The order matters. A patient with a 1 cm nodule and Child-Pugh C cirrhosis is stage D, not stage 0 — liver function and performance status are assessed before burden, not alongside it.
- A SINGLE nodule is stage 0 or A by size alone, however large. An 8 cm solitary tumour with PS 0 and preserved function is stage A, not stage B.
- The two size boundaries apply to different situations: 2 cm separates 0 from A in a solitary nodule, and 3 cm separates A from B when there are 2 or 3.
- The 2026 update preserves the 2022 stage definitions. What changed is the explicit definition of multifocal disease in stage B, plus treatment allocation within stages.
- Stage D driven by liver function rather than by tumour burden or performance status is the one situation where transplantation may still offer a route out.
Interpreting the result
Read the stage together with what produced it. Stages 0 and A are curative-intent territory, where resection, ablation and transplantation should be considered together at a multidisciplinary meeting rather than sequentially, and where portal pressure and bilirubin often matter more than the tumour in choosing between them. Stage B is conventionally treated with transarterial chemoembolisation, though a proportion of patients fall within transplant criteria or can be downstaged into them. Stage C means systemic therapy, with combination immunotherapy consolidated as preferred first line in the 2026 update. Stage D means best supportive care — with one important exception: where the stage is driven by liver function rather than by tumour burden or performance status, transplantation may still be feasible, and that is the single most important question to ask before accepting a terminal designation. Across all stages, the 2026 update introduces the CUSE framework, which asks teams to weigh complexity, uncertainty, subjectivity and emotional factors explicitly rather than treating stage allocation as automatic.
| Score | Band | What it means | Action |
|---|---|---|---|
| Stage 0 | Very early | Single nodule ≤ 2 cm, PS 0, preserved liver function. Outcomes approach those of the general population with optimal treatment | Ablation, or resection where anatomy favours it |
| Stage A | Early | Single nodule > 2 cm, or 2–3 nodules all ≤ 3 cm, PS 0, preserved function. Curative treatment is achievable | Resection, ablation or transplantation by liver function, portal pressure and anatomy; SBRT and TARE added as potentially curative in the 2026 update |
| Stage B | Intermediate | Multifocal disease — more than 3 nodules, or 2–3 with one > 3 cm — with PS 0 and preserved function | Transarterial chemoembolisation; assess against transplant criteria and consider downstaging |
| Stage C | Advanced | Portal invasion and/or extrahepatic spread, or PS 1–2, with preserved liver function | Systemic therapy; combination immunotherapy consolidated as preferred first line in the 2026 update |
| Stage D | Terminal | Any tumour burden with PS 3–4 or end-stage liver function | Best supportive care — unless the stage is driven by liver function alone, in which case assess transplant candidacy |
What the BCLC Staging needs (5 inputs)
- ECOG performance status
- 0 to 4. PS 1–2 places a patient in stage C even with a tiny tumour; PS 3–4 places them in stage D. This is assessed before tumour burden, not after.
- Liver function
- Preserved (Child-Pugh A or B) or end-stage (Child-Pugh C and not transplantable). End-stage function is stage D whatever the tumour looks like.
- Portal invasion and/or extrahepatic spread
- Either finding is stage C. Confirm that portal involvement is tumour thrombus rather than bland thrombus — they are distinguishable on contrast imaging and carry different implications.
- Number of nodules
- Single, 2–3, or more than 3. A single nodule is stage 0 or A by size however large; more than 3 nodules is stage B regardless of size.
- Largest nodule diameter
- The boundary depends on the count: 2 cm separates stage 0 from stage A in a solitary nodule, and 3 cm separates stage A from stage B when there are 2 or 3.
What it returns
- BCLC stage
- 0 (very early), A (early), B (intermediate), C (advanced) or D (terminal).
- What determined the stage
- Named explicitly, because a stage C driven by performance status alone is a different clinical conversation from one driven by portal invasion.
- Treatment framing
- The management approach associated with each stage in the 2026 update, as a starting point for multidisciplinary discussion rather than a substitute for it.
How it is calculated
BCLC treats hepatocellular carcinoma as a problem with three simultaneous constraints rather than one. Because the tumour almost always arises in a cirrhotic liver, the amount of functioning parenchyma limits what can be resected or ablated, and the patient's physical condition limits what they can tolerate. The system therefore evaluates performance status and liver function first, on the reasoning that either can make a technically treatable tumour untreatable in practice. Only when both are preserved does tumour burden decide the stage, and the burden thresholds are drawn where the evidence for particular treatments changes: 2 cm because ablation approaches resection in efficacy below it, and the Milan-adjacent limits because they mark where transplantation outcomes hold up. Each stage then carries a treatment recommendation and a survival expectation, which is the feature that distinguishes BCLC from purely anatomical staging systems and the reason both EASL and AASLD build their guidance around it.
Facts & figures
| Stage | Tumour burden | Performance status | Liver function |
|---|---|---|---|
| 0 — very early | Single nodule ≤ 2 cm | 0 | Preserved |
| A — early | Single > 2 cm, or 2–3 nodules all ≤ 3 cm | 0 | Preserved |
| B — intermediate | > 3 nodules, or 2–3 with one > 3 cm | 0 | Preserved |
| C — advanced | Portal invasion and/or extrahepatic spread | 0–2 | Preserved |
| D — terminal | Any | 3–4 | Any, or end-stage |
Stages C and D are reached by performance status or liver function alone, without reference to burden — which is why those are assessed first.
| Area | Change |
|---|---|
| Stage definitions | Unchanged from 2022 |
| Stage B | 'Multifocal' explicitly defined as > 3 nodules, or ≤ 3 nodules with at least one > 3 cm |
| Stages 0 / A | Stereotactic body radiotherapy and transarterial radioembolisation introduced as potentially curative options alongside resection and ablation |
| Stage B | Evidence held insufficient for routine locoregional plus systemic combination therapy |
| Stage C | Combination immunotherapy further consolidated as preferred first line |
| Framework | CUSE introduced — complexity, uncertainty, subjectivity and emotion weighed explicitly in multidisciplinary decisions |
Because the stage definitions themselves are unchanged, a stage assigned under the 2022 update remains valid; what has moved is the treatment allocated within each stage.
Evidence
BCLC 2026 update — Reig, Forner et al.
2026The current revision of the BCLC strategy, updating prognosis prediction and treatment recommendations while preserving the stage definitions established in the 2022 update.
Clarifies the definition of multifocal disease in stage B, introduces stereotactic body radiotherapy and transarterial radioembolisation as potentially curative options at stages 0 and A, consolidates combination immunotherapy as preferred first line at stage C, and introduces the CUSE framework for multidisciplinary decision-making.
BCLC 2022 update — the stage definitions in current use
2022The 2022 revision, which established the stage definitions carried forward unchanged into 2026 and introduced the sub-stratification of intermediate-stage disease.
Refined stage B into groups by tumour burden and liver function, and set out the treatment-stage migration concept that allows patients to receive a treatment allocated to a different stage where the recommended option is unsuitable.
EASL clinical practice guidelines
2018EASL clinical practice guidelines on the management of hepatocellular carcinoma, which adopt BCLC as the staging and treatment-allocation framework.
Establishes BCLC as the reference system for linking stage to treatment in European practice.
AASLD practice guidance
2018AASLD guidance on the diagnosis, staging and management of hepatocellular carcinoma.
Uses the BCLC framework for treatment allocation, aligning North American and European practice on the same staging language.
How it compares
BCLC Staging vs Milan criteria
Different questions — BCLC allocates treatment across all stages, while Milan answers only whether a patient is within transplant criteria.
The Milan criteria (a single lesion ≤ 5 cm, or up to three lesions each ≤ 3 cm, without vascular invasion or extrahepatic spread) define transplant eligibility and are applied within BCLC stages A and B rather than in competition with them. A patient can be BCLC stage B and still within Milan, which is exactly the situation where transplantation is considered ahead of chemoembolisation.
BCLC Staging vs Child-Pugh score
Child-Pugh is an input to BCLC, not an alternative to it — it supplies the liver function axis.
BCLC uses preserved (Child-Pugh A or B) versus end-stage (Child-Pugh C) function as one of its three axes, so the two are nested rather than competing. Child-Pugh alone says nothing about tumour burden or performance status and cannot allocate treatment in hepatocellular carcinoma.
BCLC Staging vs LI-RADS v2018
Sequential — LI-RADS establishes that a lesion is hepatocellular carcinoma, and BCLC then stages the confirmed disease.
LI-RADS categorises an observation on CT or MRI by its probability of being HCC, with LR-5 permitting a non-invasive diagnosis without biopsy. BCLC presupposes that diagnosis. Applying BCLC to an LR-3 observation stages something that has not yet been shown to be cancer.
BCLC Staging vs ALBI grade
Complementary — ALBI grades liver function more granularly than the binary preserved/end-stage split BCLC uses.
ALBI uses only bilirubin and albumin, avoiding the subjective ascites and encephalopathy items in Child-Pugh, and separates patients within Child-Pugh A who have meaningfully different reserve. Several groups use ALBI alongside BCLC to refine treatment selection within a stage, particularly when deciding between resection and less invasive options.
Pearls & pitfalls
- Assess performance status and liver function BEFORE tumour burden. A 1 cm nodule in a Child-Pugh C patient is stage D, not stage 0.
- A single nodule is stage 0 or A by size however large. An 8 cm solitary tumour with PS 0 and preserved function is stage A — size alone never creates stage B.
- The two size boundaries are not interchangeable: 2 cm separates 0 from A in a solitary nodule; 3 cm separates A from B when there are 2 or 3.
- Stage B means more than 3 nodules, or 2–3 nodules with at least one above 3 cm. The 2026 update added this wording precisely because 'multifocal' was being read inconsistently.
- Performance status 1 is enough for stage C. Clinicians routinely under-score PS in patients they know well, and that single point changes the treatment pathway entirely.
- Distinguish tumour thrombus from bland portal vein thrombosis before assigning stage C — they look similar on non-contrast imaging and mean different things.
- Stage D driven by liver function alone is not necessarily terminal. Assess transplant candidacy before accepting that designation.
- Treatment-stage migration is part of the system, not a departure from it: a patient may reasonably receive a treatment allocated to another stage when the recommended option is unsuitable.
- BCLC applies to hepatocellular carcinoma only. Intrahepatic cholangiocarcinoma and liver metastases are staged differently.
Critical actions
- Confirm the diagnosis meets non-invasive imaging criteria (LI-RADS 5 or equivalent) or obtain histology before assigning a stage and committing to treatment.
- Score performance status honestly and, where possible, independently — it is the input most vulnerable to optimism.
- Establish liver function formally with Child-Pugh, and consider portal pressure where resection is contemplated.
- Refer every case to a hepatobiliary multidisciplinary meeting; BCLC frames the discussion rather than replacing it.
- At stages 0 and A, consider resection, ablation and transplantation together rather than in sequence.
- At stage D driven by liver function, assess transplant candidacy explicitly before defaulting to supportive care.
- Re-stage at each reassessment — BCLC stage is not fixed, and both progression and improvement in liver function move it.
Why this score exists
The defining decision was to refuse to stage the tumour in isolation. Every other cancer staging system in wide use describes anatomy and leaves treatment selection to a separate step; BCLC folds liver function and performance status into the stage itself, on the argument that in a cancer arising in a failing organ those are not comorbidities but constraints on what the disease actually is. That is why a 1 cm tumour in a Child-Pugh C patient is stage D — a designation that looks harsh until you notice it is telling you something true, which is that no oncological treatment will help that person and only a new liver might. The trade-off, and the standing criticism of the system, is that bundling three axes into one label loses information, which is what the 2022 sub-stratification of stage B and the 2026 CUSE framework are both attempts to give back.
About the creator
First author, BCLC 2022 and 2026 updates; BCLC Group, Hospital Clínic Barcelona
Led the two most recent revisions of the BCLC strategy.
Co-author of the 2022 and 2026 updates and of much of the underlying BCLC evidence base.
Originator of the BCLC staging system
Developed the original BCLC framework linking stage to treatment allocation and led its successive revisions.
Limitations
- Bundles three distinct axes into a single label, so patients with the same stage can differ substantially — the reason stage B was sub-stratified in 2022 and the CUSE framework added in 2026.
- Stage C is heterogeneous, spanning a patient with PS 1 and a single nodule and one with extensive portal invasion and extrahepatic disease.
- Performance status is subjectively assessed and systematically under-scored by clinicians who know the patient, which shifts patients out of stage C incorrectly.
- The binary preserved/end-stage liver function split is coarse; Child-Pugh A and B patients are grouped together despite meaningfully different tolerance of treatment.
- Treatment recommendations evolve faster than stage definitions, so a stage assigned some years ago may carry an outdated management implication even though the stage itself is unchanged.
- Applies only to hepatocellular carcinoma, and not to intrahepatic cholangiocarcinoma, mixed tumours or metastatic disease.
- Does not account for tumour biology or biomarkers such as alpha-fetoprotein, which independently affect prognosis and transplant outcomes.
If you are the patient
BCLC is the system doctors use to describe how advanced liver cancer is and, importantly, what treatment is likely to help. Unlike staging systems for most other cancers, it does not look only at the tumour. It considers three things together: how big and how many the tumours are, how well the liver itself is working, and how well the person is in general. That is because liver cancer usually develops in a liver already damaged by cirrhosis, and the health of the rest of the liver decides what treatment is safely possible. The stages run from 0 (very early, a single small tumour, often curable) through A and B, to C (advanced) and D. Stage D usually means treatment is aimed at comfort rather than cure — but there is an important exception: if someone is in stage D mainly because their liver is failing rather than because the cancer is extensive, a liver transplant may still be an option, and that is always worth asking about.
Frequently asked questions
What is BCLC staging?#
The Barcelona Clinic Liver Cancer system, which stages hepatocellular carcinoma as 0, A, B, C or D using three axes together — tumour burden, liver function and performance status — and links each stage to a treatment recommendation.
What are the BCLC stage definitions?#
Stage 0 is a single nodule of 2 cm or less with PS 0 and preserved liver function. Stage A is a single larger nodule or 2–3 nodules all 3 cm or less. Stage B is multifocal disease — more than 3 nodules, or 2–3 with at least one above 3 cm. Stage C is portal invasion, extrahepatic spread or PS 1–2. Stage D is PS 3–4 or end-stage liver function.
What changed in the BCLC 2026 update?#
The stage definitions are unchanged from 2022. The update explicitly defines multifocal disease in stage B as more than 3 nodules or 2–3 nodules with at least one above 3 cm, adds stereotactic body radiotherapy and transarterial radioembolisation as potentially curative options at stages 0 and A, consolidates combination immunotherapy as preferred first line at stage C, and introduces the CUSE decision framework.
Is a large single tumour stage B?#
No. A single nodule is stage 0 or A by size alone, however large — an 8 cm solitary tumour with PS 0 and preserved liver function is stage A. Stage B requires multifocal disease: more than 3 nodules, or 2–3 nodules with at least one above 3 cm.
Why is a small tumour sometimes stage D?#
Because performance status and liver function are assessed before tumour burden. A 1 cm nodule in a patient with Child-Pugh C cirrhosis or ECOG 3 is stage D, since no oncological treatment will help. Where the stage is driven by liver function alone, transplantation may still be an option.
Does BCLC replace TNM staging in liver cancer?#
In practice, yes, for treatment allocation. TNM stages the tumour anatomically but does not account for liver function or performance status, both of which determine what treatment is possible in a cancer arising in a cirrhotic liver. Both EASL and AASLD build their guidance on BCLC.
What is treatment-stage migration?#
The principle, built into BCLC, that a patient may receive a treatment allocated to a different stage when the recommended option is unsuitable — for example moving to the next-best option when resection is precluded by portal hypertension. It is part of the system rather than a departure from it.
Can a patient move between BCLC stages?#
Yes, in both directions. Tumour progression moves a patient up, and improvement in liver function or performance status can move them down — which is why re-staging at each reassessment matters, and why treating a decompensation can change what is oncologically possible.
References
Original / primary reference
- Reig M, Forner A, Ávila MA, et al. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. J Hepatol. 2026;84(3):631-654.
- Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-693.
Guidelines
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
- Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-750.